BR112023019299A2 - Forma cristalina a de um composto piridopirazol substituído com flúor, seu método de preparação e uso - Google Patents

Forma cristalina a de um composto piridopirazol substituído com flúor, seu método de preparação e uso

Info

Publication number
BR112023019299A2
BR112023019299A2 BR112023019299A BR112023019299A BR112023019299A2 BR 112023019299 A2 BR112023019299 A2 BR 112023019299A2 BR 112023019299 A BR112023019299 A BR 112023019299A BR 112023019299 A BR112023019299 A BR 112023019299A BR 112023019299 A2 BR112023019299 A2 BR 112023019299A2
Authority
BR
Brazil
Prior art keywords
crystalline form
fluorine
preparation
pyridopirazole
compound substituted
Prior art date
Application number
BR112023019299A
Other languages
English (en)
Inventor
Chengde Wu
Chunli Shen
Haobin Wang
Ning Jiang
Xiawei Wei
Yuchuan Zhu
Original Assignee
Jumbo Drug Bank Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jumbo Drug Bank Co Ltd filed Critical Jumbo Drug Bank Co Ltd
Publication of BR112023019299A2 publication Critical patent/BR112023019299A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

forma cristalina a de um composto piridopirazol substituído com flúor, seu método de preparação e uso. uma forma cristalina de um composto de piridopirazol substituído com flúor e um método de preparação do mesmo. adicionalmente é fornecida uma aplicação do composto e da forma cristalina do mesmo na preparação de um fármaco para o tratamento de uma doença relacionada.
BR112023019299A 2021-03-23 2022-03-22 Forma cristalina a de um composto piridopirazol substituído com flúor, seu método de preparação e uso BR112023019299A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202110309088 2021-03-23
PCT/CN2022/082353 WO2022199591A1 (zh) 2021-03-23 2022-03-22 一种氟取代的吡啶并吡唑类化合物的晶型及其制备方法

Publications (1)

Publication Number Publication Date
BR112023019299A2 true BR112023019299A2 (pt) 2023-12-05

Family

ID=83396316

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023019299A BR112023019299A2 (pt) 2021-03-23 2022-03-22 Forma cristalina a de um composto piridopirazol substituído com flúor, seu método de preparação e uso

Country Status (8)

Country Link
EP (1) EP4303220A1 (pt)
JP (1) JP2024511614A (pt)
KR (1) KR20230154243A (pt)
CN (1) CN117769553A (pt)
AU (1) AU2022244937A1 (pt)
BR (1) BR112023019299A2 (pt)
CA (1) CA3214116A1 (pt)
WO (1) WO2022199591A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024022234A1 (zh) * 2022-07-28 2024-02-01 成都嘉葆药银医药科技有限公司 吡唑并吡啶类化合物在制备治疗包括中枢神经系统疾病的btk相关疾病的药物中的用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9637486B2 (en) * 2013-12-20 2017-05-02 Merck Sharp & Dohme Corp. Btk inhibitors
CN109851620B (zh) * 2016-08-17 2020-08-07 深圳市塔吉瑞生物医药有限公司 用于抑制酪氨酸激酶活性的稠合双环类化合物
US11739090B2 (en) * 2019-09-26 2023-08-29 Jumbo Drug Bank Co., Ltd. Substituted pyrazlo[3,4-c]pyridines as selective BTK kinase inhibitors

Also Published As

Publication number Publication date
CN117769553A (zh) 2024-03-26
JP2024511614A (ja) 2024-03-14
KR20230154243A (ko) 2023-11-07
CA3214116A1 (en) 2022-09-29
WO2022199591A1 (zh) 2022-09-29
EP4303220A1 (en) 2024-01-10
AU2022244937A1 (en) 2023-10-12

Similar Documents

Publication Publication Date Title
PE20191474A1 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cancer
NI202000099A (es) Compuestos de purinona y su uso en el tratamiento del cáncer
UY39029A (es) Uso de compuestos de aminopropionato sustituido en el tratamiento de la infección por sars-cov-2
CO2017001035A2 (es) “2-(morfolin-4-il)-1,7-naftiridinas sustituidas, composiciones y combinaciones farmacéuticas que las comprenden, y compuestos intermediarios
CO2018011935A2 (es) Derivados aromáticos de sulfonamida
AR104984A1 (es) Compuestos selectivos para pyy y sus usos
CL2019000485A1 (es) Uso de pridopidina para el tratamiento de la disminución funcional.
UY39027A (es) Uso de favipiravir en el tratamiento de la infección por coronavirus
CL2016000495A1 (es) Compuestos derivados de triazolo[4,5-d]pirimidina, agonistas de receptor cb2; proceso de preparación; composición que los comprende y el uso para el tratamiento o profilaxis del dolor, aterosclerosis, inflamación, diabetes mellitus, entre otras enfermedades.
UY37496A (es) Hemihidrato de la base libre de n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamida, métodos de fabricación y usos del mismo
ECSP17038893A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
BR112019005318A2 (pt) compostos de aza-indazol para uso em lesões no tendão e/ou ligamento
CL2019002900A1 (es) Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton.
CR20160235A (es) Tienopirimidinas como inhibidores mknk1 y mknk2
CR20160016A (es) Pirazolpiridinas sustituidas
CL2020002544A1 (es) Inhibidor de ret para uso en tratar cáncer que tiene una alteración de ret
AR112471A1 (es) Antagonistas del receptor del factor liberador de corticotropina
BR112023019299A2 (pt) Forma cristalina a de um composto piridopirazol substituído com flúor, seu método de preparação e uso
CO2021011023A2 (es) Compuesto heterocíclico, composición farmacéutica que lo comprende, método para su preparación, y uso de estos
BR112022001568A2 (pt) Composto, método para preparação do composto, composição farmacêutica, e, uso do composto
BR112022001393A2 (pt) Forma cristalina do inibidor de atr e seu uso
DOP2018000197A (es) Compuestos de cinnolin-4-amina y su uso en el tratamiento del cáncer
BR112023010891A2 (pt) Compostos polipeptídicos modificados com lactama
BR112019005578A2 (pt) compostos de indazol para uso em lesões no tendão e/ou ligamento
BR112022000155A2 (pt) Composição inibidora da micromolécula pi4kiiia, seu método de preparação, e uso da mesma